Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate CancerCameron Herberts, Alexander W. Wyatt, Andrew J. Murtha et al.|European Urology|2020Cited by 90
Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate CancerElie Ritch, Alexander W. Wyatt, Simon Fu et al.|Clinical Cancer Research|2019Cited by 77
A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503)Solmaz Sahebjam, Sebastién J. Hotte|British Journal of Cancer|2013Cited by 76
Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted <sup>18</sup>F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or EnzalutamideKatherine Zukotynski, Steven P. Rowe, Mario A. Eisenberger et al.|Journal of Nuclear Medicine|2021Cited by 52
Figure S7 from Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate CancerElie Ritch, Alexander W. Wyatt, Simon Fu et al.|Unknown|2023Cited by 0